Amended Statement of Ownership (sc 13g/a)
January 03 2019 - 11:40AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Amendment No. 1)
Under the Securities Exchange Act of 1934
Enzon Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
293904108
(CUSIP Number)
December 31, 2018
(Date of Event Which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
|
[X]
|
Rule 13d-1(b)
|
|
|
|
|
[ ]
|
Rule 13d-1(c)
|
|
|
|
|
[ ]
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions of the
Act (however, see the
Notes
).
CUSIP No.
293904108
|
13G/A
|
Page 2 of 5 Pages
|
1
|
Names of Reporting Persons
Harper Asset Management, LLC
|
2
|
Check the appropriate box if a member
of a Group (see
instructions)
(a)
[
]
(b)
[X]
|
3
|
Sec Use Only
|
4
|
Citizenship or Place of
Organization
United
States
|
Number of Shares
Beneficially
Owned by Each
Reporting Person
With:
|
5
|
Sole Voting Power
2,609,703
|
6
|
Shared Voting Power
0
|
7
|
Sole Dispositive Power
2,609,703
|
8
|
Shared Dispositive Power
0
|
9
|
Aggregate Amount Beneficially Owned
by Each Reporting Person
2,609,703
|
10
|
Check box if the aggregate amount in
row (9) excludes certain shares (See Instructions)
[
]
|
11
|
Percent of class represented by
amount in row (9)
5.9%
|
12
|
Type of Reporting Person (See
Instructions)
IA
|
CUSIP No.
293904108
|
13G/A
|
Page 3 of 5 Pages
|
Item 1.
(a)
|
Name of Issuer: Enzon Pharmaceuticals, Inc. (the
Issuer)
|
|
|
(b)
|
Address of Issuer's Principal Executive
Offices: 20 Commerce Dr., Suite 135, Cranford, NJ 07016
|
Item 2.
(a)
|
Name of Person Filing: Brian Harper
|
|
|
(b)
|
Address of Principal Business Office: 6680 Gunpark
Dr., Suite 202B, Boulder, CO 80301
|
|
|
(c)
|
Citizenship: United States
|
|
|
(d)
|
Title and Class of
Securities: Common Stock, par value $0.01 per share
|
|
|
Item 3.
|
If this statement is filed pursuant to §§
240.13d-1(b) or 240.13d-2(b) or (c), check whether the
person
filing is a:
|
|
(a)
|
[ ]
|
Broker or dealer registered under Section 15 of the Act;
|
|
|
|
|
|
(b)
|
[ ]
|
Bank as defined in Section 3(a)(6) of the Act;
|
|
|
|
|
|
(c)
|
[ ]
|
Insurance company as defined in Section 3(a)(19) of the
Act;
|
|
|
|
|
|
(d)
|
[ ]
|
Investment company registered under Section 8 of the
Investment Company Act of 1940;
|
|
|
|
|
|
(e)
|
[X]
|
An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E);
|
|
|
|
|
|
(f)
|
[ ]
|
An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F);
|
|
|
|
|
|
(g)
|
[ ]
|
A parent holding company or control person in
accordance with Rule 13d-1(b)(1)(ii)(G);
|
|
|
|
|
|
(h)
|
[ ]
|
A savings associations as defined in Section
3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
|
|
|
|
(i)
|
[ ]
|
A church plan that is excluded from the
definition of an investment company under section 3(c)(14) of the
Investment Company Act of 1940;
|
|
|
|
|
|
(j)
|
[ ]
|
A non-U.S. institution in accordance with Rule
240.13d-1(b)(1)(ii)(J);
|
|
|
|
|
|
(k)
|
[ ]
|
Group, in accordance with Rule
240.13d-1(b)(1)(ii)(K).
|
CUSIP No.
293904108
|
13G/A
|
Page 4 of 5 Pages
|
|
|
|
|
|
(a)
|
Amount Beneficially Owned:
|
|
|
|
|
|
|
As of the close of business on
December 31, 2018, Harper Asset Management, LLC beneficially owned 2,609,703
shares, which are held in investment advisory client accounts. No individual
client held more than 170,000 shares.
|
|
|
|
|
|
(b)
|
Percent of Class:
|
|
|
|
|
|
|
As of December 31, 2018, Harper Asset
Management, LLC beneficially owned approximately 5.9% of the outstanding
shares of common stock, based on 44,214,603 shares outstanding on September
30, 2018 as reported in the Issuers form 10-Q, filed with the SEC on
November 7, 2018.
|
|
|
|
|
|
(c)
|
Number of shares as to which such
person has:
|
|
|
|
|
|
|
(i)
|
Sole power to vote or to direct the vote:
See cover pages items
5-9.
|
|
|
|
|
|
|
(ii)
|
Shared power to vote or to direct the vote:
See cover pages items
5-9.
|
|
|
|
|
|
|
(iii)
|
Sole power to dispose or to direct the disposition of:
See cover
pages items 5-9.
|
|
|
|
|
|
|
(iv)
|
Shared power to dispose or to direct the disposition
of:
See cover pages items 5-9.
|
|
|
Item 5.
|
Ownership of Five Percent or Less of a
Class.
|
Not applicable.
Item 6.
|
Ownership of more than Five Percent on
Behalf of Another Person.
|
Not applicable.
Item 7.
|
Identification and classification of the
subsidiary which acquired the security being reported on
by the
parent holding company or control person.
|
Not applicable.
Item 8.
|
Identification and classification of members
of the group.
|
Not applicable.
Item 9.
|
Notice of Dissolution of Group.
|
Not applicable.
CUSIP No.
293904108
|
13G/A
|
Page 5 of 5 Pages
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: January 3, 2019
/s/ Brian Harper
Brian Harper/President
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is signed
on behalf of a person by his authorized representative (other than an executive
officer or general partner of this filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement, provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From Apr 2024 to May 2024
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From May 2023 to May 2024